Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is often coprescribed with clopidogrel for the treatment of ischemic vascular diseases. The aim of this study was to explore the effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel. 2. Twelve male rats were employed to investigate the effect of fluvoxamine on the pharmacokinetics of clopidogrel in vivo. Clopidogrel carboxylic acid was used for the pharmacokinetic study of clopidogrel. 3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0 - t (from 9850 ± 4060 to 27 300 ± 6910 µg/l h; p < 0.05), AUC0 - ∞ (from 9850 ± 4060 to 27 600 ± 6800 µg/l h; p < 0.05) and t1/2 (from 2.07 ± 0.0942 to 7.49 ± 1.22 h; p < 0.05) of clopidogrel carboxylic acid. 

 

(후략)